SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VNRX

Volitionrx Ltd (New York Stock Exchange Arca:VNRX)

US · Delayed Price · Currency is USD
Healthcare · Medical - Devices
$0.16+$0.00 (-1.58%)
 
Market cap
$1.95M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 2, 2012
Market Cap$1.95M-97.5%
Revenue (ttm)$3.44M+134.0%
Net Income-$24.06M-5.2%
EPS-$3.08+34.0%
Shares Out12.04M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,200,851
Open$0.17
Previous Close$0.16
Day's Range$0.16 - $0.17
52-Week Range$0.16 - $7.80
Beta1.16
AnalystsBuy
Price Targetn/a
Earnings DateMar 30, 2027

About VNRX

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Address
1489 West Warm Springs Road, Henderson, NV, 89014, US
Market Cap
2 million
Employees
75
Industrial Classification
Medical - Devices

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$6.85K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Distressed
From VNRX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-1.58%
5 Days
-29.21%
1 Month
-2.58%
6 Months
-94.00%
1 Year
-97.48%

$VNRX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VNRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VNRX's directors and management

No SEC Form 4 activity for VNRX in the last 5 quarters.

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VNRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New VNRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VNRX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VNRX

VXFVanguard Extended Market ETF$9.90K
STSBiShares Factors US Small Blend Style ETF$615.59

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VNRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
72

News check: Strong Q3 earnings beat with 157% revenue surge, clinical validation progress, and expanded commercial partnerships signal positive momentum and growth execution.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$6.85K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.